FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to the production of anti-tumor peptide vaccines, and can be used in medicine for treating or preventing malignant tumors accompanied by high expression of the WT1 gene. Vaccine composition contains an effective amount of peptide WT1126: Arg Met Phe Pro Asn Ala Pro Tyr Leu, peptide WT1187: Ser Leu Gly Glu Gln Gln Tyr Ser Val or modified versions thereof.
EFFECT: invention provides an effective anti-tumor response in human leukocyte antigen (HLA)-A*0206 positive individuals.
17 cl, 32 dwg, 14 ex, 25 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| VACCINE COMPOSITION FOR MALIGNANT TUMOR | 2013 |
|
RU2721574C2 |
| NEIL3 PEPTIDES AND VACCINES COMPRISING THEM | 2010 |
|
RU2733985C2 |
| HLA-A*1101-LIMITED PEPTIDE WT1 AND PHARMACEUTICAL COMPOSITION THAT CONTAINS IT | 2007 |
|
RU2481398C2 |
| PEPTIDE DERIVED FROM FOXM1, AND INCLUDING ITS VACCINE | 2016 |
|
RU2738418C2 |
| PEPTIDE OBTAINED FROM DEPDC1 AND VACCINE CONTAINING IT | 2016 |
|
RU2765574C2 |
| PEPTIDE, OBTAINED FROM MPHOSPH1, AND INCLUDING ITS VACCINE | 2016 |
|
RU2731099C2 |
| IMMUNITY INDUCER | 2017 |
|
RU2755542C2 |
| IMMUNITY INDUCER | 2016 |
|
RU2758112C2 |
| CHIMERIC ANTIBODY/T-CELL RECEPTOR STRUCTURES AND THEIR APPLICATIONS | 2016 |
|
RU2767209C2 |
| STRUCTURES AIMED AT AFP/MHC PEPTIDE COMPLEXES AND TYPES OF THEIR USE | 2016 |
|
RU2754041C2 |
